PT - JOURNAL ARTICLE AU - Karlyn K. Harrod AU - Jeffrey L. Rogers AU - Jeffrey A. Feinstein AU - Alison L. Marsden AU - Daniele E. Schiavazzi TI - Predictive modeling of secondary pulmonary hypertension in left ventricular diastolic dysfunction AID - 10.1101/2020.04.23.20073601 DP - 2021 Jan 01 TA - medRxiv PG - 2020.04.23.20073601 4099 - http://medrxiv.org/content/early/2021/02/09/2020.04.23.20073601.short 4100 - http://medrxiv.org/content/early/2021/02/09/2020.04.23.20073601.full AB - Diastolic dysfunction is a common pathology occurring in about one third of patients affected by heart failure. This condition is not associated with a marked decrease in cardiac output or systemic pressure and therefore is more difficult to diagnose than its systolic counterpart. Compromised relaxation or increased stiffness of the left ventricle with or without mitral valve stenosis induces an increase in the upstream pulmonary pressures, and is classified as secondary or group II (2018 Nice classification) pulmonary hypertension. This may result in an increase in the right ventricular afterload leading to right ventricular failure. Elevated pulmonary pressures are therefore an important clinical indicator of diastolic heart failure (sometimes referred to as heart failure with preserved ejection fraction, HFpEF), showing significant correlation with associated mortality. Accurate measurements of this quantity, however, are typically obtained through invasive catheterization, and after the onset of symptoms. In this study, we use the hemodynamic consistency of a differential-algebraic circulation model to predict pulmonary pressures in adult patients from other, possibly non-invasive, clinical data. We investigate several aspects of the problem, including the ability of model outputs to represent a sufficiently wide pathologic spectrum, identifiability of its parameters, to the accuracy of the predicted pulmonary pressures. We also find that a classifier using the assimilated model parameters as features is free from the problem of missing data and is able to detect pulmonary hypertension with sufficiently high accuracy. For a cohort of 82 patients suffering from various degrees of heart failure severity we show that systolic, diastolic and wedge pulmonary pressures can be estimated on average within 8, 6 and 6 mmHg, respectively. We also show that, in general, increased data availability leads to improved predictions.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by a Google ATAP grant, a National Institute of Health grant 1R01EB018302, a National Science Foundation grant CDS&E (PI Alison Marsden) and a NSF Big Data Science & Engineering grant #1918692 (PI Daniele Schiavazzi). The authors would also like to thank Derek DeBusschere and Sandy Ng for their guidance and supervision. This research used computational resources provided through the Center for Research Computing at the University of Notre Dame. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Compliance with Ethical Standards - The study was classified as research not involving human subjects and approved on June 13th, 2019 by the Office of Research Compliance and Institutional Review Board at the University of Notre Dame under IRB#19-05-5371. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. For this retrospective study formal consent is not required.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe EHR data set used in the paper will be made available as additional material when the paper will be published.